EMA Recommends Approval of Sarclisa Subcutaneous Injection for Multiple Myeloma
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy SNY?
Source: NASDAQ.COM
- Positive EMA Opinion: The European Medicines Agency's Committee has adopted a positive opinion recommending the approval of Sarclisa (isatuximab) subcutaneous injection for multiple myeloma patients, covering all current indications, marking a significant advancement in treatment options.
- First Subcutaneous Anticancer Drug: If approved, Sarclisa subcutaneous injection will be the first anticancer treatment administered via an on-body injector, enhancing patient convenience and potentially transforming the treatment landscape for multiple myeloma.
- Positive Market Reaction: Sanofi shares rose by 1.54% to €82.40, reflecting market optimism regarding the approval prospects of Sarclisa subcutaneous injection, which could enhance the company's competitiveness in the oncology market.
- Innovative Delivery Method: The Sarclisa subcutaneous injection will offer both subcutaneous and manual injection options, increasing patient choice and aligning with personalized medicine trends, further solidifying Sanofi's leadership in cancer treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 46.620
Low
57.00
Averages
79.36
High
119.07
Current: 46.620
Low
57.00
Averages
79.36
High
119.07
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sanofi's Amlitelimab Phase 3 Data Shows Promising Efficacy
- Clinical Trial Results: Sanofi's phase 3 studies, COAST 1, COAST 2, and SHORE, demonstrate that its experimental eczema drug, amlitelimab, meets key efficacy endpoints, showing progressively increasing efficacy without plateau at Week 24, indicating its potential in treating moderate-to-severe atopic dermatitis patients.
- Dosing Frequency Advantage: The data support a Q12W dosing regimen for amlitelimab, allowing patients to experience less frequent dosing, which enhances adherence and quality of life, addressing the urgent needs of moderate-to-severe atopic dermatitis patients.
- Medical Need Fulfillment: Despite existing medications, a significant medical gap remains for moderate-to-severe atopic dermatitis, and Sanofi's findings suggest that amlitelimab can effectively reduce disease severity and burdensome symptoms, further driving the demand for new treatment options.
- Strategic Implications: Sanofi plans to file for global regulatory approvals, which is expected to lay the groundwork for profitable growth over the next five years, and the successful launch of amlitelimab will significantly enhance the company's market position in the eczema treatment sector.
See More
FDA Accelerates Biosimilar Drug Development and Approves New Treatments
- Accelerated Biosimilar Development: On March 9, 2026, the FDA recommended streamlining unnecessary clinical pharmacokinetic studies when scientifically justified, aiming to expedite biosimilar drug development and improve medicine affordability, thereby enhancing market competitiveness.
- Alternative to Animal Testing: The FDA released draft guidance on March 18, 2026, to assist drug developers in validating new approach methodologies as alternatives to animal testing, reflecting its commitment to scientific rigor and humane practices, which could reshape drug development standards.
- New Therapy Approval: On March 10, 2026, the FDA approved Wellcovorin as the first treatment for cerebral folate deficiency, a rare neurological condition, marking a significant advancement in neuroscience and potentially offering new hope for patients.
- Gene Therapy Innovation: The FDA approved Rocket Pharma's Kresladi on March 26, 2026, as the first gene therapy for Severe Leukocyte Adhesion Deficiency Type I, showcasing the potential of gene therapy in treating rare diseases and possibly driving stock price increases for related biotech companies.
See More
Sanofi Reports Positive Results from Three Phase 3 Trials of Amlitelimab
- Clinical Trial Results: Sanofi presented encouraging results from three Phase 3 trials at the 2026 AAD Annual Meeting, demonstrating that amlitelimab significantly improves skin clearance and disease severity in patients with moderate-to-severe atopic dermatitis, highlighting its potential as an effective treatment option.
- Primary Endpoint Achieved: In both COAST 1 and COAST 2 trials, amlitelimab met the primary endpoint with a 2-point reduction in vIGA-AD scores, showcasing treatment efficacy, particularly in COAST 1 where significant improvements in EASI-75 and PP-NRS further support its clinical application.
- Combination Therapy Effectiveness: The SHORE study indicated that amlitelimab, when combined with topical corticosteroids, produced significant improvements in AD symptoms across both Q4W and Q12W dosing regimens, demonstrating flexibility and effectiveness in different administration frequencies.
- Good Safety Profile: Across all three studies, amlitelimab was generally well-tolerated, with a safety profile consistent with previously reported data, suggesting its potential safety for long-term use and laying a foundation for future clinical applications.
See More
Zacks Research Daily: Major Stock Analyses
- Palantir's Strong Performance: Palantir's shares have surged 71.9% over the past year, significantly outperforming the Internet Software industry at -6.8%, driven by a robust AI strategy that enhances service capabilities for government and commercial clients, although the lack of dividends may deter income-focused investors.
- Linde's Consistent Growth: Linde's shares increased by 4.0% over the past year, outperforming the Chemical Specialty industry at 0.8%, supported by a stable project pipeline and strong capital discipline, yet a weak outlook for Europe and falling helium prices could pressure future growth.
- Arista's Resilient Performance: Arista's shares have outperformed the Internet Software industry over the past six months, despite intense competition in cloud networking, with innovative products and steady customer additions driving revenue growth, though rising costs and supply chain constraints pose risks.
- Comstock's Strong Execution: Comstock's shares have soared 225.7% over the past two years, far exceeding the Building Products industry at -29.3%, benefiting from strong execution in transit-oriented projects and strategic acquisitions that enhance brand value and income, although rising labor costs and weak cash flow may pressure margins.
See More
EMA Endorses Sanofi's Scarlisa for On-Body Injection Approval
- Regulatory Progress: The European Medicines Agency's Committee has adopted a positive opinion for Sanofi's Scarlisa (isatuximab) subcutaneous formulation, which, if approved, would be the only oncologic drug in the EU administered via on-body injection, significantly enhancing Sanofi's competitive edge in the oncology market.
- Multiple Myeloma Treatment: Scarlisa is already approved for multiple myeloma, and its potential approval for on-body injection could provide patients with a more convenient administration method, likely improving adherence and driving market share growth for Sanofi in this therapeutic area.
- Optimistic Market Outlook: Sanofi anticipates continued profitable growth over the next five years, and the approval of Scarlisa would further solidify its position in the oncology drug market, contributing positively to the company's overall performance.
- Management Transition Impact: Under the leadership of new CEO Belén Garijo, Sanofi is focused on project rejuvenation; although former CEO Paul Hudson left some projects unfinished, the potential success of new drugs like Scarlisa could provide fresh growth momentum for the company.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Sanofi's Amlitelimab Phase 3 Data Shows Promising Efficacy
- Clinical Trial Results: Sanofi's phase 3 studies, COAST 1, COAST 2, and SHORE, demonstrate that its experimental eczema drug, amlitelimab, meets key efficacy endpoints, showing progressively increasing efficacy without plateau at Week 24, indicating its potential in treating moderate-to-severe atopic dermatitis patients.
- Dosing Frequency Advantage: The data support a Q12W dosing regimen for amlitelimab, allowing patients to experience less frequent dosing, which enhances adherence and quality of life, addressing the urgent needs of moderate-to-severe atopic dermatitis patients.
- Medical Need Fulfillment: Despite existing medications, a significant medical gap remains for moderate-to-severe atopic dermatitis, and Sanofi's findings suggest that amlitelimab can effectively reduce disease severity and burdensome symptoms, further driving the demand for new treatment options.
- Strategic Implications: Sanofi plans to file for global regulatory approvals, which is expected to lay the groundwork for profitable growth over the next five years, and the successful launch of amlitelimab will significantly enhance the company's market position in the eczema treatment sector.
See More
FDA Accelerates Biosimilar Drug Development and Approves New Treatments
- Accelerated Biosimilar Development: On March 9, 2026, the FDA recommended streamlining unnecessary clinical pharmacokinetic studies when scientifically justified, aiming to expedite biosimilar drug development and improve medicine affordability, thereby enhancing market competitiveness.
- Alternative to Animal Testing: The FDA released draft guidance on March 18, 2026, to assist drug developers in validating new approach methodologies as alternatives to animal testing, reflecting its commitment to scientific rigor and humane practices, which could reshape drug development standards.
- New Therapy Approval: On March 10, 2026, the FDA approved Wellcovorin as the first treatment for cerebral folate deficiency, a rare neurological condition, marking a significant advancement in neuroscience and potentially offering new hope for patients.
- Gene Therapy Innovation: The FDA approved Rocket Pharma's Kresladi on March 26, 2026, as the first gene therapy for Severe Leukocyte Adhesion Deficiency Type I, showcasing the potential of gene therapy in treating rare diseases and possibly driving stock price increases for related biotech companies.
See More
Sanofi Reports Positive Results from Three Phase 3 Trials of Amlitelimab
- Clinical Trial Results: Sanofi presented encouraging results from three Phase 3 trials at the 2026 AAD Annual Meeting, demonstrating that amlitelimab significantly improves skin clearance and disease severity in patients with moderate-to-severe atopic dermatitis, highlighting its potential as an effective treatment option.
- Primary Endpoint Achieved: In both COAST 1 and COAST 2 trials, amlitelimab met the primary endpoint with a 2-point reduction in vIGA-AD scores, showcasing treatment efficacy, particularly in COAST 1 where significant improvements in EASI-75 and PP-NRS further support its clinical application.
- Combination Therapy Effectiveness: The SHORE study indicated that amlitelimab, when combined with topical corticosteroids, produced significant improvements in AD symptoms across both Q4W and Q12W dosing regimens, demonstrating flexibility and effectiveness in different administration frequencies.
- Good Safety Profile: Across all three studies, amlitelimab was generally well-tolerated, with a safety profile consistent with previously reported data, suggesting its potential safety for long-term use and laying a foundation for future clinical applications.
See More
Zacks Research Daily: Major Stock Analyses
- Palantir's Strong Performance: Palantir's shares have surged 71.9% over the past year, significantly outperforming the Internet Software industry at -6.8%, driven by a robust AI strategy that enhances service capabilities for government and commercial clients, although the lack of dividends may deter income-focused investors.
- Linde's Consistent Growth: Linde's shares increased by 4.0% over the past year, outperforming the Chemical Specialty industry at 0.8%, supported by a stable project pipeline and strong capital discipline, yet a weak outlook for Europe and falling helium prices could pressure future growth.
- Arista's Resilient Performance: Arista's shares have outperformed the Internet Software industry over the past six months, despite intense competition in cloud networking, with innovative products and steady customer additions driving revenue growth, though rising costs and supply chain constraints pose risks.
- Comstock's Strong Execution: Comstock's shares have soared 225.7% over the past two years, far exceeding the Building Products industry at -29.3%, benefiting from strong execution in transit-oriented projects and strategic acquisitions that enhance brand value and income, although rising labor costs and weak cash flow may pressure margins.
See More
EMA Endorses Sanofi's Scarlisa for On-Body Injection Approval
- Regulatory Progress: The European Medicines Agency's Committee has adopted a positive opinion for Sanofi's Scarlisa (isatuximab) subcutaneous formulation, which, if approved, would be the only oncologic drug in the EU administered via on-body injection, significantly enhancing Sanofi's competitive edge in the oncology market.
- Multiple Myeloma Treatment: Scarlisa is already approved for multiple myeloma, and its potential approval for on-body injection could provide patients with a more convenient administration method, likely improving adherence and driving market share growth for Sanofi in this therapeutic area.
- Optimistic Market Outlook: Sanofi anticipates continued profitable growth over the next five years, and the approval of Scarlisa would further solidify its position in the oncology drug market, contributing positively to the company's overall performance.
- Management Transition Impact: Under the leadership of new CEO Belén Garijo, Sanofi is focused on project rejuvenation; although former CEO Paul Hudson left some projects unfinished, the potential success of new drugs like Scarlisa could provide fresh growth momentum for the company.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
